🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to have recognized Jeremiah Wala here ASCO receiving the Dr Felix Fang Young Investigator Award. J&J Innovative Medicine we are humbled to support this award remembering Dr Felix Fang who we will miss but know his work will go on via these young investigators. #ASCO25 #MyCompany

Great to speak with Vanessa Broadhurst J&J Innovative Medicine here #ASCO25 on the #RedCouch with patient advocate Nichelle on the progress we have made in #NSCLC by advancing the science and giving patients more hope and time. #MyCompany

Great to see Jill Feldman present results from #COCOON here at #ASCO25 on quality of life and prevention of skin reactions. At J&J Innovative Medicine we work collaboratively with all in the medical community to advance care for patients. #MyCompany

📢 #ASCO25 | mCRPC Ph. I | KLK2×CD3 bispecific pasritamig: First-in-human (n = 174) shows PSA50 42.4%, median rPFS 6.8 m; G≥3 TRAEs 9.2%, no CRS > G1. by Dr. #CapucineBaldini from Gustave Roussy et al. Full abstract → [shorturl.at/meFe4] ASCO The ASCO Post Journal of Clinical Oncology

The power of cellular immunotherapy ! Impressive results! Congratulations ! ⁦Journal of Clinical Oncology⁩ ⁦IACH⁩ ⁦COMy⁩ ⁦ASCO⁩

For US #HCPs at #ASCO25: see Dr. Gerhardt Attard present late-breaking data from the Phase 3 AMPLITUDE trial in metastatic castration-sensitive #ProstateCancer patients with alterations in homologous recombination repair genes.

Breaking news ASCO #ASCO25 👉 1st biomarker selected, positive ph3 trial in mHSPC #ProstateCancer 👉Abiraterone+ niraparib/PARPi significant improve rPFS (favorable OS trend) in HRR+ pts (⬆️benefit in BRCApts), NGS testing must inall AttardLab PCF Science UroToday.com OncoAlert

Outstanding results from the FLAIR study presented at #EHA25 today and published in the ⁦NEJM⁩. #MyCompany nejm.org/doi/full/10.10…

Great to see this novel combination data getting presented at #EHA2025 as new therapies are needed for patients with myeloma and extra medullary disease. #MyCompany prnewswire.com/news-releases/…

Terrific interview by AJMC with Sundar Jagannath from #EHA2025 describing the updated CARTITUDE-1 results. #MyCompany ajmc.com/view/cartitude… via @AJMC

Love to see the research we support in my home country papers ⁦The Guardian⁩. #MyCompany theguardian.com/science/2025/j…

Excited for our new investigational ⁦J&J Innovative Medicine⁩ dual targeting CAR T-cell therapy. Data presented at #EHA2025. #MyCompany jnj.com/media-center/p…

Innovation is at the heart of what we do ⁦J&J Innovative Medicine⁩ innovating to bring new medicines to patients. Great interview with our CEO ⁦JoaquinDuato⁩. #MyCompany bloomberg.com/news/videos/20…